Real-world data highlights faricimab’s effectiveness in patients with treatment-experienced nAMD
Faricimab provides significant anatomical improvements and extends treatment intervals in treatment-experienced patients with neovascular age-related macular degeneration (nAMD), while maintaining vision and potentially reducing the treatment burden, according to results from a real-world study.
The single-center retrospective study included 184 patients (215 eyes) who switched to faricimab after receiving an average of 18 prior anti-VEGF injections over 5 years. Results at 12 months showed a slight decrease in best-corrected visual acuity (BCVA), with median BCVA dropping from 70 to 62 ETDRS letters. However, significant anatomical improvement was noted, as median central macular thickness (CMT) reduced from 259.5 μm to 232 μm.
Faricimab treatment also extended dosing intervals. The median interval increased from 4 to 8 weeks, with 47.4% of eyes achieving intervals of 8-12 weeks and 16.3% exceeding 12 weeks. At the final follow-up, 40.2% of eyes were dry on OCT imaging.
Although 3 cases of uveitis were observed following the loading phase, the findings suggest that faricimab offers substantial benefits in managing nAMD.
Reference
Janmohamed IK, Mushtaq A, Kabbani J, et al. 1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration. Eye (Lond). 2025;doi: 10.1038/s41433-025-03616-5. Epub ahead of print. PMID: 39863706.
Related Content
